1315 Capital II Amends INTERPACE BIOSCIENCES Stake

TL;DR

1315 Capital II updated its 13D filing for INTERPACE BIOSCIENCES, INC. on 10/16/24.

AI Summary

On October 16, 2024, 1315 Capital II, L.P. filed an amendment (No. 5) to its Schedule 13D regarding its holdings in INTERPACE BIOSCIENCES, INC. The filing indicates a change in beneficial ownership, though specific new holdings or changes in percentage are not detailed in this excerpt. The filing is an update to previous disclosures concerning the company's common stock.

Why It Matters

This filing signals a potential shift in major shareholder activity for INTERPACE BIOSCIENCES, INC., which could influence stock price and corporate strategy.

Risk Assessment

Risk Level: medium — Schedule 13D filings often indicate significant investor activity, which can lead to volatility and strategic changes for the company.

Key Players & Entities

• 1315 Capital II, L.P. (company) — Filing entity
• INTERPACE BIOSCIENCES, INC. (company) — Subject company
• 20241016 (date) — Filing date

FAQ

Key Financial Figures

• $0.01 — INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securiti
• $1,000 — tial stated value per Series C share of $1,000 divided by an initial conversion price
• $2.02 — vided by an initial conversion price of $2.02 per share and then multiplied by the nu

Filing Documents

• formsc13da.htm (SC 13D/A) — 110KB
• 0001493152-24-041309.txt ( ) — 112KB

From the Filing

SC 13D/A 1 formsc13da.htm UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5 )* INTERPACE BIOSCIENCES, INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 46062X 303 (CUSIP Number) 1315 Capital II, L.P. 1315 Capital Management II, LLC 2929 Walnut Street, Suite 1240 Philadelphia, PA 19104 Telephone: (215) 662-1315 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) October 11, 2024 (Date of Event Which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of § 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box . Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of section 18 of the Securities Exchange Act of 1934 (“ Act ”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). SCHEDULE 13D CUSIP No. 46062X 303 Page 2 of 7 Pages 1 NAME OF REPORTING PERSONS 1315 Capital II, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) (b) 3 SEC USE ONLY 4 SOURCE OF FUNDS (See Instructions) OO 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) 6 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7 SOLE VOTING POWER 0 8 SHARED VOTING POWER 9,405,940 (1) 9 SOLE DISPOSITIVE POWER 0 10 SHARED DISPOSITIVE POWER 9,405,940 (1) 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9,405,940 (1) 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 68% (2) 14 TYPE OF REPORTING PERSON (See Instructions) PN (1) Evidenced by 19,000 shares of Series C Convertible Preferred Stock, par value $0.01 per share (the “ Series C ”), of Interpace Biosciences, Inc. (the “ Issuer ”). The Series C is convertible from time to time, at the option of the holder thereof, into a number of shares of common stock, par value $0.01 per share, of the Issuer (the “ Common Stock ”), equal to the initial stated value per Series C share of $1,000 divided by an initial conversion price of $2.02 per share and then multiplied by the number of shares of Series C to be converted. (2) This percentage (a) is calculated based upon 4,394,312 shares of Common Stock outstanding as of August 2, 2024, as disclosed in the Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024 filed by the Issuer on August 8, 2024 and (b) assumes the conversion of all 19,000 outstanding shares of Series C owned by 1315 Capital into an aggregate 9,405,940 shares of Common Stock. However, if all 47,000 outstanding shares of Series C were converted into an aggregate of 23,267,326 shares of Common Stock, 1315 Capital would own 34%. SCHEDULE 13D CUSIP No. 46062X 303 Page 3 of 7 Pages 1 NAME OF REPORTING PERSONS 1315 Capital Management II, LLC 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) (b) 3 SEC USE ONLY 4 SOURCE OF FUNDS (See Instructions) OO 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) 6 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7 SOLE VOTING POWER 0 8 SHARED VOTING POWER 9,405,940 (1) 9 SOLE DISPOSITIVE POWER 0 10 SHARED DISPOSITIVE POWER 9,405,940 (1) 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9,405,940 (1) 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 68 % (2) 14 TYPE OF REPORTING PERSON (See Instructions) OO (1) Evidenced by 19,000 shares of Series C. The shares of Series C are convertible from time to time, at the option of the holder thereof, into a number of shares of Common Stock equal to the initial stated value per Series C

View Full Filing

View this SC 13D/A filing on SEC EDGAR